AZN
February 8, 2024 - AI Summary
Undervalued by 1.4% based on the discounted cash flow analysis.
Market cap | $205.22 Billion |
---|---|
Enterprise Value | $227.88 Billion |
Dividend Yield | $1.436 (2.17%) |
Earnings per Share | $1.91 |
Beta | 0.54 |
Outstanding Shares | 3,100,411,036 |
Avg 30 Day Volume | 5,095,984 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 34.46 |
---|---|
PEG | 507.31 |
Price to Sales | 4.84 |
Price to Book Ratio | 5.65 |
Enterprise Value to Revenue | 4.97 |
Enterprise Value to EBIT | 32.8 |
Enterprise Value to Net Income | 38 |
Total Debt to Enterprise | 0.13 |
Debt to Equity | 0.73 |
No data
No data
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...